Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
BOAN BIOTECH (06955.HK) Boluojia New Indication Approved in China
Recommend 1 Positive 1 Negative 0 |
||||
|
||||
|
BOAN BIOTECH (06955.HK) announced that the National Medical Products Administration of China has approved the supplemental application for a new indication of Boluojia (Denosumab Injection 120mg). The new indication is for the treatment of patients with bone metastases from solid tumors or multiple myeloma, to delay or reduce the risk of skeletal-related events (pathological fractures, spinal cord compression, bone radiation therapy or bone surgery). Boluojia is a biosimilar of Xgeva, independently developed by the company based on its global strategy. The product was first approved for launch in China in May 2024 for the treatment of giant cell tumor of bone. The company is also accelerating the commercialization process of Boluojia in more countries and regions worldwide. Currently, Boluojia has successfully completed international multi-center Phase III clinical trials in Europe, the United States and Japan. Its marketing application in the United Kingdom is also under review. The company plans to initiate marketing filings for the product in the United States, the European Union, Japan and other high-potential international markets. (sl/da) Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
